Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.
Böhm S, Wustrau K, Pachlopnik Schmid J, Prader S, Ahlmann M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, Jordan M, Marsh R, Naumann-Bartsch N, Mauz-Körholz C, Hönig M, Schulz A, Malinowska I, Hines M, Nichols KE, Gil-Herrera J, Talano JA, Crooks B, Formankova R, Jorch N, Bakhtiar S, Kühnle I, Streiter M, Nathrath M, Russo A, Dürken M, Lang P, Lindemans C, Henter JI, Lehmberg K, Ehl S. Böhm S, et al. Among authors: jorch n. Blood. 2024 Mar 7;143(10):872-881. doi: 10.1182/blood.2023022281. Blood. 2024. PMID: 37992218
Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5).
Pagel J, Beutel K, Lehmberg K, Koch F, Maul-Pavicic A, Rohlfs AK, Al-Jefri A, Beier R, Bomme Ousager L, Ehlert K, Gross-Wieltsch U, Jorch N, Kremens B, Pekrun A, Sparber-Sauer M, Mejstrikova E, Wawer A, Ehl S, zur Stadt U, Janka G. Pagel J, et al. Among authors: jorch n. Blood. 2012 Jun 21;119(25):6016-24. doi: 10.1182/blood-2011-12-398958. Epub 2012 Mar 26. Blood. 2012. PMID: 22451424 Free article.
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer ML, Pieters R, Horstmann MA, Janka-Schaub GE, Escherich G. Schramm F, et al. Among authors: jorch n. Blood Adv. 2019 Nov 26;3(22):3688-3699. doi: 10.1182/bloodadvances.2019000576. Blood Adv. 2019. PMID: 31765480 Free PMC article.
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: jorch n. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).
Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Classen CF, Corbacioglu S, Dirksen U, Ebetsberger-Dachs G, Heinzerling L, Jorch N, Kuhlen M, Lawlor J, Niggli F, Streiter M, Schneider DT, Brecht I. Offenmueller S, et al. Among authors: jorch n. Klin Padiatr. 2017 Nov;229(6):322-328. doi: 10.1055/s-0043-118662. Epub 2017 Oct 10. Klin Padiatr. 2017. PMID: 29017184 English.
50 results